drug · antibody
patient view →ravulizumab LA
Marketedupdated 2mo agoby Alexion Pharmaceuticals Inc🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $3.9B
community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for hemolytic-uremic syndrome and paroxysmal nocturnal hemoglobinuria and 11 investigational indications.
targets
Complement C5
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that